Genentech and Biogen Idec announce top-line results from a Phase II/III clinical trial of Rituxan in primary-progressive multiple sclerosis Genentech, 14 Apr 2008 Accessed on 4 Jan 2012 from http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=11147. CommentRecommendBookmarkWatch